Product Description
Mechanisms of Action: Radioactive Agent
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Atom Technology Co., Ltd.
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: China
Active Clinical Trial Count: 3
Highest Development Phases
Phase 3: Bone Marrow Diseases|Oncology Unspecified
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
BJK-Z-F18HN-202010-YZGK | P3 |
Completed |
Bone Marrow Diseases |
2022-06-02 |
|
CTR20210217 | P3 |
Not yet recruiting |
Oncology Unspecified |
None |
|
CTR20201663 | P3 |
Recruiting |
Oncology Unspecified |
None |